A Phase 2, Randomized Study of Bortezomib/Dexamethasone With or Without Elotuzumab in Subjects With Relapsed/Refractory Multiple Myeloma.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jun 2016
At a glance
- Drugs Elotuzumab (Primary) ; Bortezomib; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Proof of concept; Therapeutic Use
- Sponsors Bristol-Myers Squibb
- 07 Jun 2017 Biomarkers information updated
- 05 Jun 2016 This trial was Completed in Spain, according to the European Clinical Trials Database.
- 16 May 2016 Planned End Date changed from 1 Apr 2016 to 1 Aug 2016.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History